Investor Profile: Oxford Science Enterprises — Thesis, Cheque Size & How to Apply

Thesis

Oxford Science Enterprises (OSE) is an independent investment company created in 2015 to found, fund and build companies from research at the University of Oxford. It is the university's preferred partner for spinouts, working with academics at Oxford and innovators at the Harwell and Culham science campuses. Its model is venture building as much as venture investing: OSE co-creates companies from laboratory breakthroughs, assembles founding teams, and stays invested from inception through scale.

The focus is transformational science, not incremental software, across life sciences, health technology and deep technology. That long horizon shapes its willingness to fund at the earliest stages and its hands-on help with hiring, fundraising and international expansion.

Sectors and stages

OSE invests from pre-seed and seed through to growth, a leading seed investor in UK spinouts. Its sectors span drug discovery, medical technology, quantum computing, advanced materials, energy and robotics. The common thread is a single origin: world-class Oxford science with a credible path to a large market.

The portfolio is anchored in the Oxford cluster, though its companies raise and sell globally, syndicated with more than 300 co-investors, mentors and strategic partners.

Fund size and cheque size

OSE says it has raised over £850 million from global investors and that, together with its co-investors, it has invested more than £3 billion into Oxford spinouts. Earlier reporting put its assets under management above $1 billion, making it one of the largest university-linked funds focused on a single institution. A standard cheque size is not publicly disclosed, and amounts are set case by case.

Notable portfolio

OSE-backed companies include Oxford Quantum Circuits and Oxford Ionics in quantum computing, PQShield in post-quantum cryptography, and Wild Bioscience, which raised a $60 million Series A co-investment from OSE and the Ellison Institute of Technology. Recent names include Stateful Robotics ($4.8 million raised) and Densix ($4 million seed round). Dark Blue Therapeutics was acquired in a deal worth up to $840 million.

Partners and team

OSE is led by chief executive Ed Bussey. Senior investment leadership includes Sam Harman, partner and head of deep tech, Heather Roxborough, senior partner and head of healthtech, and Katya Smirnyagina, senior partner for life sciences. The firm also runs entrepreneur and scientist residency programmes, embedding experienced operators and researchers with investment teams to shape new ventures.

Programs, credits and perks

Its Entrepreneurs-in-Residence programme offers seasoned entrepreneurs salaried 18-month residencies to co-found ventures from Oxford science, with a clear path to an OSE-backed spinout. A parallel Scientists-in-Residence programme embeds researchers in investment teams to validate ideas. Portfolio companies also get help with recruitment, fundraising, property, legal and marketing support. OSE does not publish a general startup credits catalogue.

How to apply for funding

There is no open application portal for general founders, because OSE's route runs through Oxford research. Academics working on breakthrough Oxford research can start a conversation through its researcher contact route, and learning how to get funding from Oxford Science Enterprises begins with that discussion: the firm assesses commercial potential, helps shape the plan and team, and decides case by case whether to found or fund the spinout. Founders outside Oxford should not pitch OSE cold; its mandate is the Oxford ecosystem.